{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=38", "query": { "condition": "Relapsed/Refractory", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 3666, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T16:49:58.857Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00090090", "title": "Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma", "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Elsamitrucin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2004-04", "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2008-01-15", "last_synced_at": "2026-11-14T16:49:58.857Z", "location_count": 7, "location_summary": "Berkeley, California • Burbank, California • Los Angeles, California + 3 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00090090" }, { "nct_id": "NCT03711058", "title": "Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor", "Microsatellite Stable (MSS) Colon Cancer" ], "interventions": [ { "name": "Copanlisib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2019-01-17", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-11-14T16:49:58.857Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03711058" }, { "nct_id": "NCT03662126", "title": "KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Primary Myelofibrosis (PMF)", "Post-Polycythemia Vera MF (Post-PV-MF)", "Post-Essential Thrombocythemia MF (Post-ET-MF)" ], "interventions": [ { "name": "KRT-232", "type": "DRUG" }, { "name": "Best Available Therapy (BAT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 385, "start_date": "2019-01-15", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2023-04-28", "last_synced_at": "2026-11-14T16:49:58.857Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03662126" }, { "nct_id": "NCT00549185", "title": "Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Non-Hodgkin" ], "interventions": [ { "name": "SAR3419", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2007-10", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-02-14", "last_synced_at": "2026-11-14T16:49:58.857Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00549185" }, { "nct_id": "NCT06660368", "title": "BCL2i CLAG-M in R/R Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 52, "start_date": "2024-11-26", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-11-14T16:49:58.857Z", "location_count": 2, "location_summary": "Tampa, Florida • Boston, Massachusetts", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06660368" }, { "nct_id": "NCT03250338", "title": "Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations" ], "interventions": [ { "name": "Crenolanib", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arog Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 106, "start_date": "2018-08-16", "completion_date": "2026-04-03", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-11-14T16:49:58.857Z", "location_count": 9, "location_summary": "Sacramento, California • Gainesville, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03250338" }, { "nct_id": "NCT05210374", "title": "Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Sarcomas" ], "interventions": [ { "name": "Disulfiram", "type": "DRUG" }, { "name": "Copper Gluconate", "type": "DRUG" }, { "name": "Liposomal Doxorubicin (Doxil)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-03-09", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-14T16:49:58.857Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05210374" }, { "nct_id": "NCT05572515", "title": "A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 614, "start_date": "2023-03-29", "completion_date": "2031-08-31", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-14T16:49:58.857Z", "location_count": 30, "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Berkeley, California + 25 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05572515" }, { "nct_id": "NCT04566978", "title": "89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Large B-cell Lymphoma", "DLBCL" ], "interventions": [ { "name": "89Zr-DFO-REGN3767", "type": "DRUG" }, { "name": "PET/CT", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-09-11", "completion_date": "2025-03-21", "has_results": false, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-11-14T16:49:58.857Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566978" }, { "nct_id": "NCT00867568", "title": "TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Medulloblastoma", "Relapse" ], "interventions": [ { "name": "TPI 287", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 18, "start_date": "2009-03", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-11-14T16:49:58.857Z", "location_count": 6, "location_summary": "San Diego, California • Orlando, Florida • St Louis, Missouri + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00867568" } ] }